Abstract
Ovarian cancer (OC) is one of the most common and dreadful cancer types which has affected the female population worldwide with an increased number of cases. Broadly, OC has been categorized into two types based on its mutational changes. These are Type 1 OC which is found to show less aggressive tumors without any mutation of the tumor protein p53 gene and Type 2 OC which exhibits tumors resulting from significant mutation of the P53 gene. The major molecular pathways and cellular targets responsible for the progression of OC include VEGF, PDGF, FGF, (PI3K)/AKT pathway, PARP, and others. The conventional therapies for the management of OC include surgery, chemotherapy, hormonal therapy, radiotherapy, monoclonal antibodies, and others. However, conventional therapies are restricted due to a few limitations such as unintended toxicities, relapse of the conditions, high dose, less bioavailability, and prolonged therapeutic regimen. Thus, to overcome these limitations nanotherapeutic approaches can be used for the effective delivery of drugs with superior targetability and negligible or no toxicity. In this chapter, we have discussed the major molecular pathways and cellular targets causing ovarian cancer. Also, the significant role of nanotherapeutic approaches and targeting mechanisms of encapsulated bioactive/drugs against ovarian cancer cells is summarized.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Alizadeh L, Alizadeh E, Zarebkohan A, Ahmadi E, Rahmati-Yamchi M, Salehi R (2020) AS1411 aptamer-functionalized chitosan-silica nanoparticles for targeted delivery of epigallocatechin gallate to the Skov-3 ovarian cancer cell lines. J Nanopart Res 22(1):9123. https://doi.org/10.1007/s11051-019-4735-7
Amini A, Masoumi Moghaddam S, Morris DL, Pourgholami MH (2012) Utility of vascular endothelial growth factor inhibitors in the treatment of ovarian cancer: from concept to application. J Oncol 2012:540791. https://doi.org/10.1155/2012/540791
Astete CE, Sabliov CM (2006) Synthesis and characterization of PLGA nanoparticles. J Biomater Sci Polym Ed 17(3):247–289. https://doi.org/10.1163/156856206775997322
AstraZeneca (2016, December-2021, January) Olaparib tablets as a treatment for ovarian cancer subjects with different hrd tumor status. Identifier NCT02983799. https://clinicaltrials.gov/ct2/show/NCT02983799?term=olaparib &recrs=e&cond=Ovarian+Cancer&draw=2&rank=5. Accessed on 14 Jan, 2022
Babu A, Wang Q, Muralidharan R, Shanker M, Munshi A, Ramesh R (2014) Chitosan coated polylactic acid nanoparticle-mediated combinatorial delivery of cisplatin and siRNA/plasmid DNA chemosensitizes cisplatin-resistant human ovarian cancer cells. Mol Pharm [Internet] 11(8):2720–2733. https://doi.org/10.1021/mp500259e. Accessed on 28, Nov, 2021
Barkat HA, Barkat MA, Taleuzzaman M, Das SS, Rizwanullah M, Hadi HA (2021) Receptor-based combinatorial nanomedicines: a new Hope for cancer management. In: Kumar S, Rizvi MA, Verma S (eds) Handbook of research on advancements in cancer therapeutics. IGI Global, pp 339–355. https://doi.org/10.4018/978-1-7998-6530-8.ch011
Barkat HA, Das SS, Barkat MA, Beg S, Hadi HA (2020) Selective targeting of cancer signaling pathways with nanomedicines: challenges and progress. Future Oncol 16(35):2959–2979. https://doi.org/10.2217/fon-2020-0198
Barlin JN, Dao F, Bou Zgheib N, Ferguson SE, Sabbatini PJ, Hensley ML, Bell-McGuinn KM, Konner J, Tew WP, Aghajanian C, Chi DS (2012) Progression-free and overall survival of a modified outpatient regimen of primary intravenous/intraperitoneal paclitaxel and intraperitoneal cisplatin in ovarian, fallopian tube, and primary peritoneal cancer. Gynecol Oncol 125(3):621–624. https://doi.org/10.1016/j.ygyno.2012.03.027
Bartlett DW, Davis ME (2007) Physicochemical and biological characterization of targeted, nucleic acid-containing nanoparticles. Bioconjug Chem 18(2):456–468. https://doi.org/10.1021/bc0603539
Bast RC Jr, Feeney M, Lazarus H, Nadler LM, Colvin RB, Knapp RC (1981) Reactivity of a monoclonal antibody with human ovarian carcinoma. J Clin Invest 68(5):1331–1337. https://doi.org/10.1172/jci110380
Becker DA, Leath CA 3rd, Walters-Haygood CL, Smith BQ, Bevis KS (2019) Utilization of an alternative docetaxel-based intraperitoneal chemotherapy regimen in patients with ovarian, fallopian tube or primary peritoneal carcinoma: a continued need for ovarian cancer patients. Am J Clin Oncol 42(1):12–16. https://doi.org/10.1097/COC.0000000000000468
Béduneau A, Saulnier P, Hindré F, Clavreul A, Leroux JC, Benoit JP (2007) Design of targeted lipid nanocapsules by conjugation of whole antibodies and antibody Fab’ fragments. Biomaterials 28(33):4978–4990. https://doi.org/10.1016/j.biomaterials.2007.05.014
Bharadwaj P, Das SS, Beg S, Rahman M (2021) Formulation and biological stability of nanomedicines in cancer treatment. In: Beg S, Choudhry H, Ahmad FJ, Rahman M, Souto EB (eds) Nanoformulation strategies for cancer treatment-micro and Nano Technologies. Elsevier, pp 277–289. https://doi.org/10.1016/C2019-0-01815-8
Burger RA (2011) Overview of anti-angiogenic agents in development for ovarian cancer. Gynecol Oncol 121(1):230–238. https://doi.org/10.1016/j.ygyno.2010.11.035
Cai L, Xu G, Shi C, Guo D, Wang X, Luo J (2015) Telodendrimer nanocarrier for co-delivery of paclitaxel and cisplatin: a synergistic combination nanotherapy for ovarian cancer treatment. Biomaterials 37:456–468. https://doi.org/10.1016/j.biomaterials.2014.10.044
Chan JK, Brady W, Monk BJ, Brown J, Shahin MS, Rose PG, Kim JH, Secord AA, Walker JL, Gershenson DM (2018) A phase II evaluation of sunitinib in the treatment of persistent or recurrent clear cell ovarian carcinoma: an NRG oncology/Gynecologic oncology group study (GOG-254). Gynecol Oncol 150(2):247–252. https://doi.org/10.1016/j.ygyno.2018.05.029
Chen M, Jin Y, Bi Y, Yin J, Wang Y, Pan L (2014) A survival analysis comparing women with ovarian low-grade serous carcinoma to those with high-grade histology. Onco Targets Ther 7:1891–1899. https://doi.org/10.2147/OTT.S67812
Chenjie X, Yuan Z, Kohler N, Kim J, Chung MA, Sun S (2009) J Am Chem Soc 131(42):15346–15351. https://doi.org/10.1021/ja905938a
Cirstoiu-Hapca A, Buchegger F, Lange N, Bossy L, Gurny R, Delie F (2010) Benefit of anti-HER2-coated paclitaxel-loaded immuno-nanoparticles in the treatment of disseminated ovarian cancer: therapeutic efficacy and biodistribution in mice. J Control Release 144(3):324–331. https://doi.org/10.1016/j.jconrel.2010.02.026
Cruz AF, Caleiras MB, Fonseca NA, Gonçalves N, Mendes VM, Sampaio SF, Moura V, Melo JB, Almeida RD, Manadas B, Simões S, Moreira JN (2021) The enhanced efficacy of intracellular delivery of doxorubicin/C6-ceramide combination mediated by the F3 peptide/Nucleolin system is supported by the downregulation of the PI3K/Akt pathway. Cancers 13(12):3052. https://doi.org/10.3390/cancers13123052
Cruz A, Mota P, Ramos C, Pires RF, Mendes C, Silva JP, Nunes SC, Bonifácio VDB, Serpa J (2020) Polyurea dendrimer folate-targeted Nanodelivery of l-Buthionine sulfoximine as a tool to tackle ovarian cancer Chemoresistance. Antioxidants (Basel) 9(2):133. https://doi.org/10.3390/antiox9020133
Danhier F, Feron O, Préat V (2010) To exploit the tumor microenvironment: passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. J Control Release 148(2):135–146. https://doi.org/10.1016/j.jconrel.2010.08.027
Das SS, Alkahtani S, Bharadwaj P, Ansari MT, ALKahtani MDF, Pang Z, Hasnain MS, Nayak AK, Aminabhavi TM (2020b) Molecular insights and novel approaches for targeting tumor metastasis. Int J Pharm 30(585):119556. https://doi.org/10.1016/j.ijpharm.2020.119556
Das PM, Bast RC Jr (2008) Early detection of ovarian cancer. Biomark Med 2(3):291–303. https://doi.org/10.2217/17520363.2.3.291
Das SS, Bharadwaj P, Bilal M, Barani M, Rahdar A, Taboada P, Bungau S, Kyzas GZ (2020c) Stimuli-responsive polymeric Nanocarriers for drug delivery, imaging, and Theragnosis. Polymers (Basel) 12(6):1397. https://doi.org/10.3390/polym12061397
Das SS, Hussain A, Verma PRP, Imam SS, Altamimi MA, Alshehri S, Singh SK (2020d) Recent advances in liposomal drug delivery system of quercetin for cancer targeting: a mechanistic approach. Curr Drug Deliv 17(10):845–860. https://doi.org/10.2174/1567201817666200415112657
Das SS, Verma PRP, Kar S, Singh SK (2020a) Quercetin-loaded nanomedicine as oncotherapy. In: Rahman M, Beg S, Kumar V, Ahmad FJ (eds) Nanomedicine for bioactives: healthcare applications, 1st edn. Springer, Singapore, pp 155–183. https://doi.org/10.1007/978-981-15-1664-1_5
Desale SS, Soni KS, Romanova S, Cohen SM, Bronich TK (2015) Targeted delivery of platinum-taxane combination therapy in ovarian cancer. J Control Release 220(Pt B):651–659. https://doi.org/10.1016/j.jconrel.2015.09.007
Drugs@FDA: FDA-Approved Drugs (n.d.-a) US-FDA https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overviewprocess&ApplNo=125418. Accessed on 14 Jan, 2022
Drugs@FDA: FDA-Approved Drugs (n.d.-b) US-FDA https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021923lbl.pdf. Accessed on 14 Jan, 2022
Drugs@FDA: FDA-Approved Drugs (n.d.-c) US-FDA https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=BasicSearch. process. Accessed on 14 Jan, 2022
Ducie J, Dao F, Considine M, Olvera N, Shaw PA, Kurman RJ, Shih IM, Soslow RA, Cope L, Levine DA (2017) Molecular analysis of high-grade serous ovarian carcinoma with and without associated serous tubal intra-epithelial carcinoma. Nat Commun 8(1):990. https://doi.org/10.1038/s41467-017-01217-9
Elit L, Oliver TK, Covens A, Kwon J, Fung MF, Hirte HW, Oza AM (2007) Intraperitoneal chemotherapy in the first-line treatment of women with stage III epithelial ovarian cancer: a systematic review with metaanalyses. Cancer 109(4):692–702. https://doi.org/10.1002/cncr.22466
Fathi M, Majidi S, Zangabad PS, Barar J, Erfan-Niya H, Omidi Y (2018) Chitosan-based multifunctional nanomedicines and theranostics for targeted therapy of cancer. Med Res Rev 38(6):2110–2136. https://doi.org/10.1002/med.21506
FDA approves ramucirumab plus erlotinib for first-line metastatic NSCLC (n.d.) US-FDA https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-ramucirumab-plus-erlotinib-first-line-metastatic-nsclc. Accessed on 14 Jan, 2022
Feng ST, Li J, Luo Y, Yin T, Cai H, Wang Y, Dong Z, Shuai X, Li ZP (2014) pH-sensitive nanomicelles for controlled and efficient drug delivery to human colorectal carcinoma LoVo cells. PLoS One 9(6):e100732. https://doi.org/10.1371/journal.pone.0100732
Ferlay J, Colombet M, Soerjomataram I, Mathers C, Parkin DM, Piñeros M, Znaor A, Bray F (2019) Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer 144(8):1941–1953. https://doi.org/10.1002/ijc.31937
Fraguas-Sánchez AI, Torres-Suárez AI, Cohen M, Delie F, Bastida-Ruiz D, Yart L, Martin-Sabroso C, Fernández-Carballido A (2020) PLGA nanoparticles for the intraperitoneal administration of CBD in the treatment of ovarian cancer: in vitro and in Ovo assessment. Pharmaceutics [Internet] MDPI AG 12(5):439. https://doi.org/10.3390/pharmaceutics12050439
Garbuzenko O, Barenholz Y, Priev A (2005) Effect of grafted PEG on liposome size and on compressibility and packing of lipid bilayer. Chem Phys Lipids 135(2):117–129. https://doi.org/10.1016/j.chemphyslip.2005.02.003
Han S, Dwivedi P, Mangrio FA, Dwivedi M, Khatik R, Cohn DE, Si T, Xu RX (2019) Sustained release paclitaxel-loaded core-shell-structured solid lipid microparticles for intraperitoneal chemotherapy of ovarian cancer. Artif Cells Nanomed Biotechnol 47(1):957–967. https://doi.org/10.1080/21691401.2019.1576705
Harter P, Sehouli J, Reuss A, Baumann K, Hanker L, Kimmig R, Schröder W, Burges A, Gropp-Meier M, Kurzeder C, Mahner S, Canzler U, Lück HJ, Meier W, Fehm T, du Bois A (2016) Phase II study evaluating PegLiposomal doxorubicin and carboplatin combination chemotherapy in Gynecologic sarcomas and mixed epithelial-mesenchymal Tumors a phase II protocol of the Arbeitsgemeinschaft Gynaekologische Onkologie study group (AGO-GYN 7). Int J Gynecol Cancer 26(9):1636–1641. https://doi.org/10.1097/IGC.0000000000000831
Horák D, Pustovyy VI, Babinskyi AV, Palyvoda OM, Chekhun VF, Todor IN, Kuzmenko OI (2017) Enhanced antitumor activity of surface-modified iron oxide nanoparticles and an α-tocopherol derivative in a rat model of mammary gland carcinosarcoma. Int J Nanomedicine 12:4257–4268. https://doi.org/10.2147/IJN.S137574
Illum L, Davis SS, Müller RH, Mak E, West P (1987) The organ distribution and circulation time of intravenously injected colloidal carriers sterically stabilized with a block copolymer–poloxamine 908. Life Sci 40(4):367–374. https://doi.org/10.1016/0024-3205(87)90138-x
İnce İ, Yıldırım Y, Güler G, Medine Eİ, Ballıca G, Kuşdemir BC et al (2020) Synthesis and characterization of folic acid-chitosan nanoparticles loaded with thymoquinone to target ovarian cancer cells. J Radioanal Nucl Chem 324(1):71–85. https://doi.org/10.1007/s10967-020-07058-z
Jacobs IJ, Menon U (2004) Progress and challenges in screening for early detection of ovarian cancer. Mol Cell Proteomics 3(4):355–366. https://doi.org/10.1074/mcp.R400006-MCP200
Janssen M, Oyen WJ, Massuger LF, Frielink C, Dijkgraaf I, Edwards DS, Radjopadhye M, Corstens FH, Boerman OC (2002) Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. Cancer Biother Radiopharm 17(6):641–646. https://doi.org/10.1089/108497802320970244
Kasper B, Hohenberger P (2011) Pazopanib: a promising new agent in the treatment of soft tissue sarcomas. Future Oncol 7(12):1373–1383. https://doi.org/10.2217/fon.11.116
Katchman BA, Chowell D, Wallstrom G, Vitonis AF, LaBaer J, Cramer DW, Anderson KS (2017) Autoantibody biomarkers for the detection of serous ovarian cancer. Gynecol Oncol 146(1):129–136. https://doi.org/10.1016/j.ygyno.2017.04.005
Kirkpatrick GJ, Plumb JA, Sutcliffe OB, Flint DJ, Wheate NJ (2011) Evaluation of anionic half generation 3.5-6.5 poly(amidoamine) dendrimers as delivery vehicles for the active component of the anticancer drug cisplatin. J Inorg Biochem 105(9):1115–1122. https://doi.org/10.1016/j.jinorgbio.2011.05.017
Kok PS, Beale P, O'Connell RL, Grant P, Bonaventura T, Scurry J, Antill Y, Goh J, Sjoquist K, De Fazio A, Mapagu C, Amant F, Friedlander M (2019) PARAGON investigators. PARAGON (ANZGOG-0903): a phase 2 study of anastrozole in asymptomatic patients with estrogen and progesterone receptor-positive recurrent ovarian cancer and CA125 progression. J Gynecol Oncol 30(5):e86. https://doi.org/10.3802/jgo.2019.30.e86
Krieger ML, Eckstein N, Schneider V, Koch M, Royer HD, Jaehde U, Bendas G (2010) Overcoming cisplatin resistance of ovarian cancer cells by targeted liposomes in vitro. Int J Pharm 389(1–2):10–17. https://doi.org/10.1016/j.ijpharm.2009.12.061
Kurman RJ, IeM S (2010) The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 34(3):433–443. https://doi.org/10.1097/PAS.0b013e3181cf3d79
Lee MK, Lim SJ, Kim CK (2007) Preparation, characterization and in vitro cytotoxicity of paclitaxel-loaded sterically stabilized solid lipid nanoparticles. Biomaterials 28(12):2137–2146. https://doi.org/10.1016/j.biomaterials.2007.01.014
McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M (1996) Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334(1):1–6. https://doi.org/10.1056/NEJM199601043340101
Michy T, Massias T, Bernard C, Vanwonterghem L, Henry M, Guidetti M, Royal G, Coll JL, Texier I, Josserand V, Hurbin AA (2019) Verteporfin-loaded lipid nanoparticles improve ovarian cancer photodynamic therapy in vitro and in vivo. Cancers (Basel) 11(11):1760. https://doi.org/10.3390/cancers11111760
Milane L, Duan Z, Amiji M (2011) Development of EGFR-targeted polymer blend nanocarriers for combination paclitaxel/lonidamine delivery to treat multi-drug resistance in human breast and ovarian tumor cells. Mol Pharm 8(1):185–203. https://doi.org/10.1021/mp1002653
Moore RG, Maclaughlan S (2010) Current clinical use of biomarkers for epithelial ovarian cancer. Curr Opin Oncol 22(5):492–497. https://doi.org/10.1097/CCO.0b013e32833c3351
Muddineti OS, Kumari P, Ray E, Ghosh B, Biswas S (2017 Jun) Curcumin-loaded chitosan-cholesterol micelles: evaluation in monolayers and 3D cancer spheroid model. Nanomedicine (Lond) 12(12):1435–1453. https://doi.org/10.2217/nnm-2017-0036
Mutlu-Agardan NB, Sarisozen C, Torchilin VP (2020) Cytotoxicity of novel redox sensitive PEG2000-S-S-PTX micelles against drug-resistant ovarian and breast cancer cells. Pharm Res 37(3):65. https://doi.org/10.1007/s11095-020-2759-4
Noorani L, Stenzel M, Liang R, Pourgholami MH, Morris DL (2015) Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model. J Nanobiotechnology. 13:25. https://doi.org/10.1186/s12951-015-0082-8
Novartis Pharmaceuticals (2009, March–2013, December) Efficacy and safety of pazopanib monotherapy after first line chemotherapy in ovarian, fallopian tube, or primary peritoneal cancer. Identifier NCT00866697. https://clinicaltrials.gov/ct2/show/NCT00866697?term=pazopanib&cond=Ovarian+Cancer&draw=2&rank=9. Accessed on 14 Jan, 2022
Pan Q, Tian J, Zhu H, Hong L, Mao Z, Oliveira JM, Reis RL, Li X (2020) Tumor-targeting Polycaprolactone nanoparticles with Codelivery of paclitaxel and IR780 for combinational therapy of drug-resistant ovarian cancer. ACS Biomater Sci Eng 6(4):2175–2185. https://doi.org/10.1021/acsbiomaterials.0c00163
Pantshwa JM, Kondiah PPD, Choonara YE, Marimuthu T, Pillay V (2020) Nanodrug delivery Systems for the Treatment of ovarian cancer. Cancers (Basel). 12(1):213. https://doi.org/10.3390/cancers12010213
Pignata S, Cannella L, Leopardo D, Pisano C, Bruni GS, Facchini G (2011) Chemotherapy in epithelial ovarian cancer. Cancer Lett 303(2):73–83. https://doi.org/10.1016/j.canlet.2011.01.026
Prat J (2014) FIGO committee on Gynecologic oncology. Staging classification for cancer of the ovary, fallopian tube, and peritoneum. Int J Gynaecol Obstet 124(1):1–5. https://doi.org/10.1016/j.ijgo.2013.10.001
Qi Z, Yin L, Xu Y, Wang F (2018) Pegylated liposomal-paclitaxel induces ovarian cancer cell apoptosis via TNF-induced ERK/AKT signaling pathway. Mol Med Rep 17(6):7497–7504. https://doi.org/10.3892/mmr.2018.8811
Rai B, Bansal A, Patel FD, Sharma SC (2014) Radiotherapy for ovarian cancers–redefining the role. Asian Pac J Cancer Prev 15(12):4759–4763. https://doi.org/10.7314/apjcp.2014.15.12.4759
Ramalingam V, Mohan Harshavardhan S, Kumar D, Malathi S, devi. (2020) Wet chemical mediated hematite α-Fe2O3 nanoparticles synthesis: preparation, characterization and anticancer activity against human metastatic ovarian cancer. Journal of Alloys and Compounds 834:155118. https://doi.org/10.1016/j.jallcom.2020.155118
Sánchez-Ramírez DR, Domínguez-Ríos R, Juárez J, Valdés M, Hassan N, Quintero-Ramos A, Del Toro-Arreola A, Barbosa S, Taboada P, Topete A, Daneri-Navarro A (2020) Biodegradable photoresponsive nanoparticles for chemo-, photothermal- and photodynamic therapy of ovarian cancer. Mater Sci Eng C Mater Biol Appl 116:111196. https://doi.org/10.1016/j.msec.2020.111196
Santoiemma PP, Powell DJ Jr (2015) Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther 16(6):807–820. https://doi.org/10.1080/15384047.2015.1040960
Sarojini S, Tamir A, Lim H, Li S, Zhang S, Goy A, Pecora A, Suh KS (2012) Early detection biomarkers for ovarian cancer. J Oncol 2012:709049. https://doi.org/10.1155/2012/709049
Shaaban AM, Rezvani M, Elsayes KM, Baskin H Jr, Mourad A, Foster BR, Jarboe EA, Menias CO (2014) Ovarian malignant germ cell tumors: cellular classification and clinical and imaging features. Radiographics 34(3):777–801. https://doi.org/10.1148/rg.343130067
Shaikh IM, Tan KB, Chaudhury A, Liu Y, Tan BJ, Tan BM, Chiu GN (2013) Liposome co-encapsulation of synergistic combination of irinotecan and doxorubicin for the treatment of intraperitoneally grown ovarian tumor xenograft. J Control Release 172(3):852–861
Sivasankarapillai V, Das SS, Sabir F, Sundaramahalingam M, Colmenares J, Prasannakumar S, Rajan M, Rahdar A, Kyzas G (2021) Progress in natural polymer engineered biomaterials for transdermal drug delivery systems. Materials Today Chemistry 19:100382. https://doi.org/10.1016/j.mtchem.2020.100382
Song H, Sgouros G (2011) Radioimmunotherapy of solid tumors: searching for the right target. Curr Drug Deliv 8(1):26–44. https://doi.org/10.2174/156720111793663651
Tayama S, Motohara T, Narantuya D, Li C, Fujimoto K, Sakaguchi I, Tashiro H, Saya H, Nagano O, Katabuchi H (2017) The impact of EpCAM expression on response to chemotherapy and clinical outcomes in patients with epithelial ovarian cancer. Oncotarget 8(27):44312–44325. https://doi.org/10.18632/oncotarget.17871
Tewari D, Java JJ, Salani R, Armstrong DK, Markman M, Herzog T, Monk BJ, Chan JK (2015) Long-term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol 33(13):1460–1466. https://doi.org/10.1200/JCO.2014.55.9898
Tirelli N, Lutolf MP, Napoli A, Hubbell JA (2002) Poly(ethylene glycol) block copolymers. J Biotechnol 90(1):3–15. https://doi.org/10.1016/s1389-0352(01)00057-5
Torchilin VP (2006) Multifunctional nanocarriers. Adv Drug Deliv Rev 58(14):1532–1555. https://doi.org/10.1016/j.addr.2006.09.009
Ulbrich K, Hekmatara T, Herbert E, Kreuter J (2009) Transferrin- and transferrin-receptor-antibody-modified nanoparticles enable drug delivery across the blood-brain barrier (BBB). Eur J Pharm Biopharm 71(2):251–256. https://doi.org/10.1016/j.ejpb.2008.08.021
Uster PS, Allen TM, Daniel BE, Mendez CJ, Newman MS, Zhu GZ (1996) Insertion of poly(ethylene glycol) derivatized phospholipid into pre-formed liposomes results in prolonged in vivo circulation time. FEBS Lett 386(2–3):243–246. https://doi.org/10.1016/0014-5793(96)00452-8
van Vlerken LE, Vyas TK, Amiji MM (2007) Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery. Pharm Res 24(8):1405–1414. https://doi.org/10.1007/s11095-007-9284-6
Varki A, Cummings RD, Esko JD, Stanley P, Hart GW, Aebi M, et al. Essentials of Glycobiology (3rd). Cold Spring Harbor (NY): Cold Spring Harbor Laboratory Press; 2015–2017. https://www.ncbi.nlm.nih.gov/books/NBK310274/
Vergara D, Bellomo C, Zhang X, Vergaro V, Tinelli A, Lorusso V, Rinaldi R, Lvov YM, Leporatti S, Maffia M (2012) Lapatinib/paclitaxel polyelectrolyte nanocapsules for overcoming multidrug resistance in ovarian cancer. Nanomedicine 8(6):891–899. https://doi.org/10.1016/j.nano.2011.10.014
Vergote I, du Bois A, Floquet A, Rau J, Kim JW, Del Campo JM, Friedlander M, Pignata S, Fujiwara K, Colombo N, Mirza MR, Monk BJ, Tsibulak I, Calvert PM, Herzog TJ, Hanker LC, Meunier J, Lee JY, Bologna A, Carrasco-Alfonso MJ, Harter P (2019) Overall survival results of AGO-OVAR16: a phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. Gynecol Oncol 155(2):186–191. https://doi.org/10.1016/j.ygyno.2019.08.024
Vilos C, Morales FA, Solar PA, Herrera NS, Gonzalez-Nilo FD, Aguayo DA, Mendoza HL, Comer J, Bravo ML, Gonzalez PA, Kato S, Cuello MA, Alonso C, Bravo EJ, Bustamante EI, Owen GI, Velasquez LA (2013) Paclitaxel-PHBV nanoparticles and their toxicity to endometrial and primary ovarian cancer cells. Biomaterials 34(16):4098–4108. https://doi.org/10.1016/j.biomaterials.2013.02.034
Wang P, Fang L (2021) Salpingo-oophorectomy versus cystectomy in patients with borderline ovarian tumors: a systemic review and meta-analysis on postoperative recurrence and fertility. World J Surg Oncol 19(1):132. https://doi.org/10.1186/s12957-021-02241-2
Wilken JA, Webster KT, Maihle NJ (2010) Trastuzumab sensitizes ovarian cancer cells to EGFR-targeted therapeutics. J Ovarian Res 3:7. https://doi.org/10.1186/1757-2215-3-7
Yu F, Jiang F, Tang X, Wang B (2018) N-octyl-N-arginine-chitosan micelles for gambogic acid intravenous delivery: characterization, cell uptake, pharmacokinetics, and biodistribution. Drug Dev Ind Pharm 44(4):615–623. https://doi.org/10.1080/03639045.2017.1405973
Yuan MQ, Zhu F, Lou JY, Yuan WM, Fu L, Liu S, Zhang ZZ, Liu CY, He Q (2014) The anti-tumoral efficacy of a docetaxel-loaded liposomal drug delivery system modified with transferrin for ovarian cancer. Drug Res (Stuttg) 64(4):195–202. https://doi.org/10.1055/s-0033-1355335
Zalipsky S, Mullah N, Harding JA, Gittelman J, Guo L, DeFrees SA (1997) Poly(ethylene glycol)-grafted liposomes with oligopeptide or oligosaccharide ligands appended to the termini of the polymer chains. Bioconjug Chem 8(2):111–118. https://doi.org/10.1021/bc9600832
Zhang Y (2008) Progress and challenges in protein structure prediction. Curr Opin Struct Biol 18(3):342–348. https://doi.org/10.1016/j.sbi.2008.02.004
Zhang XY, Chen J, Zheng YF, Gao XL, Kang Y, Liu JC, Cheng MJ, Sun H, Xu CJ (2009b) Follicle-stimulating hormone peptide can facilitate paclitaxel nanoparticles to target ovarian carcinoma in vivo. Cancer Res 69(16):6506–6514. https://doi.org/10.1158/0008-5472.CAN-08-4721
Zhang Z, Jia L, Feng Y, Zheng W (2009a) Overexpression of follicle-stimulating hormone receptor facilitates the development of ovarian epithelial cancer. Cancer Lett 278(1):56–64. https://doi.org/10.1016/j.canlet.2008.12.024
Zhi D, Yang T, Yang J, Fu S, Zhang S (2020) Targeting strategies for superparamagnetic iron oxide nanoparticles in cancer therapy. Acta Biomater 102:13–34. https://doi.org/10.1016/j.actbio.2019.11.027
Zhou M, Luo Y, Zeng W, Yang X, Chen T, Zhang L, He X, Yi X, Li Y, Yi X (2021) A co-delivery system based on a dimeric prodrug and star-shaped polymeric prodrug micelles for drug delivery. Front Chem 9:765021. https://doi.org/10.3389/fchem.2021.765021
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd.
About this chapter
Cite this chapter
Das, S.S., Moitra, I., Das, S., Singh, N., Verma, P.R.P., Singh, S.K. (2022). Conventional to Nanoscale-Based Carrier Systems in the Management of Ovarian Cancer. In: Rahman, M., H Almalki, W., Alrobaian, M., Beg, S., Alharbi, K.S. (eds) Hormone Related Cancer Mechanistic and Nanomedicines. Springer, Singapore. https://doi.org/10.1007/978-981-19-5558-7_5
Download citation
DOI: https://doi.org/10.1007/978-981-19-5558-7_5
Published:
Publisher Name: Springer, Singapore
Print ISBN: 978-981-19-5557-0
Online ISBN: 978-981-19-5558-7
eBook Packages: MedicineMedicine (R0)